Monopar Therapeutics is a clinical-stage biopharmaceutical company building a pipeline around radiopharmaceuticals and other specialty drugs for serious disease. Its MNPR-101 programs target the uPAR pathway on advanced solid tumors, pairing diagnostic imaging agents with therapeutic isotopes such as lutetium and actinium. The company also advances late-stage assets outside pure oncology, including work related to Wilson disease, aiming to address conditions with limited treatment options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -2.5 | — |
| Q3 2025 | 0 | — | -3.4 | — |
| Q4 2025 | 0 | — | -5.2 | — |
| Q1 2026 | 0 | — | -3.9 | — |
| Q2 2026 | 0 | — | -5.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: General Catalyst Global Resilience Merger Corp. (GCGR), QVC Group Inc. (QVCG), Gravity Co., Ltd. (GRVY), Kura Sushi USA, Inc. (KRUS), Gemini Space Station, Inc. (GEMI), Materialise NV (MTLS)